Prognostic model for second progression‐free survival and overall survival in patients with high‐risk metastatic hormone‐sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy

Documenti analoghi

• Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone‐sensitive prostate cancer: A multicenter study
  di: Takafumi Yanagisawa, et al.
  Pubblicazione: (2024)
• Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma
  di: Masanao Shinohara, et al.
  Pubblicazione: (2026)
• Deferred Cytoreductive Nephrectomy in Unresectable/Metastatic Renal Cell Carcinoma: A Real‐World Multicenter Retrospective Study
  di: Ryuma Tanaka, et al.
  Pubblicazione: (2026)
• Androgen‐Deprivation Therapy and Dietary Habits Influence the Gut Microbial Environment in Patients With High‐Risk Localized Prostate Cancer
  di: Masanori Ishida, et al.
  Pubblicazione: (2025)
• Arterio–ureteral fistula from a pseudoaneurysm of the right common iliac artery after robot‐assisted laparoscopic radical cystectomy: A case report
  di: Taketoshi Nara, et al.
  Pubblicazione: (2024)